1430720-10-7

HS-438 is a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.

HS-438 is a potent and selective BCR-ABL inhibitor. HS-438 shows antiproliferative activity. HS-438 decreases the expression of phosphorylation of BCR-ABL (Tyr177). HS-438 induces apoptosis and cell cycle arrest at G0/G1 phase. HS-438 shows antitumor activity. HS-438 has the potential for the research of chronic myeloid leukemia (CML)[1].

[1] Yun SM, et al. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Cancer Lett. 2014 Jun 28;348(1-2):50-60. DOI:10.1016/j.canlet.2014.03.012